Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 3,600 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 3,600 shares of the stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $9.88 per share, with a total value of $35,568.00. Following the transaction, the chief executive officer now owns 5,570,602 shares of the company’s stock, valued at $55,037,547.76. This trade represents a 0.06 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, April 17th, Snehal Patel acquired 5,400 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $8.98 per share, for a total transaction of $48,492.00.
• On Monday, April 7th, Snehal Patel purchased 3,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, April 4th, Snehal Patel acquired 5,500 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $8.73 per share, with a total value of $48,015.00.

Greenwich LifeSciences Price Performance

Shares of GLSI opened at $9.98 on Friday. Greenwich LifeSciences, Inc. has a 12 month low of $8.06 and a 12 month high of $18.75. The stock’s 50-day moving average is $10.47 and its two-hundred day moving average is $12.15. The stock has a market cap of $132.47 million, a PE ratio of -12.47 and a beta of 1.76.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.40). On average, research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the period. GAMMA Investing LLC purchased a new stake in shares of Greenwich LifeSciences during the first quarter worth about $126,000. Bank of America Corp DE lifted its stake in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares in the last quarter. Northern Trust Corp boosted its holdings in Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after purchasing an additional 12,923 shares during the last quarter. Finally, Barclays PLC grew its stake in Greenwich LifeSciences by 12.7% during the 4th quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after purchasing an additional 1,088 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright raised their target price on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, April 21st.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.